{
  "docId": "019de074-c46c-7261-862e-11078609bbd6",
  "docSlug": "94ed059236b735624310519badaf5152",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 32 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 32,
  "prevPage": 31,
  "nextPage": null,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 64,
  "notes": "Includes cash position note and footnotes regarding share-based compensation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-c46c-7261-862e-11078609bbd6/32",
  "deckHref": "/decks/019de074-c46c-7261-862e-11078609bbd6",
  "deckJsonHref": "/decks/019de074-c46c-7261-862e-11078609bbd6.json",
  "deckAnchorHref": "/decks/019de074-c46c-7261-862e-11078609bbd6#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1. Cash, cash equivalents and marketable securities. 2. Amounts include share-based compensation.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32e0250a-6f00-41e5-857a-add3d2e45849",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "subtitle",
      "text": "$327.5 million cash1 as of December 31, 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbf2b8e1-a9b5-4be2-907c-55bf1cadc5bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "table",
      "text": "Financial statement table showing Revenue, Costs and expenses, Loss from continuing operations, Income from discontinued operations, and Share-based compensation expense.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9639e66-2365-42d1-9744-1a5bb85abc00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Fourth Quarter 2022 Financials",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cd7fd4e-03e8-4b56-a13d-4f82cad106bc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 32,
      "from": 31,
      "beatId": "653cb9b2-f4dc-4a41-a395-91b29037039e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "The presentation provides a financial update, including Q4 2022 financial highlights and a capital return program.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}